Abstract
Interferons are first immunomodulatory molecules that have been shown to display a wide range of applications due to their antiviral, antibacterial, antitumor, and inflammatory activities. Natural and recombinant interferons are among most common biologic therapeutics worldwide. Interferon inducers, however, are less known and have been mostly developed and used in former socialist countries. Despite the fact that they are virtually unknown to the Western world, they represent a substantial market share of modern pharmacopoeia in former socialist republics. This review provides a brief description of most popular interferon inducers including Amyxin, Amizon, Anandin, Arbidol, Blasten, Cycloferon, Galavit, Groprinosine, Hepon, Immunoxel, Dzherelo, Kagocel, Larifan, Ligfol, Likopid, Mebavin, MIGI-KLP, V-5 Immunitor, SCV-07, Milife, Neovir, Poludan, Ragocin, Ridostin, Thymogen and Savratz, some of which were in use for several decades for the same clinical indications as for interferons. The variety and choice offered by the pharmaceutical industry behind the former “iron curtain” certainly deserves the appreciation, familiarity and application prospects for medical and research investigators worldwide.
Current Pharmaceutical Design
Title: Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Volume: 15 Issue: 11
Author(s): Dmytro S. Silin, Oksana V. Lyubomska, Feliks I. Ershov, Valeriy M. Frolov and Galyna A. Kutsyna
Affiliation:
Abstract: Interferons are first immunomodulatory molecules that have been shown to display a wide range of applications due to their antiviral, antibacterial, antitumor, and inflammatory activities. Natural and recombinant interferons are among most common biologic therapeutics worldwide. Interferon inducers, however, are less known and have been mostly developed and used in former socialist countries. Despite the fact that they are virtually unknown to the Western world, they represent a substantial market share of modern pharmacopoeia in former socialist republics. This review provides a brief description of most popular interferon inducers including Amyxin, Amizon, Anandin, Arbidol, Blasten, Cycloferon, Galavit, Groprinosine, Hepon, Immunoxel, Dzherelo, Kagocel, Larifan, Ligfol, Likopid, Mebavin, MIGI-KLP, V-5 Immunitor, SCV-07, Milife, Neovir, Poludan, Ragocin, Ridostin, Thymogen and Savratz, some of which were in use for several decades for the same clinical indications as for interferons. The variety and choice offered by the pharmaceutical industry behind the former “iron curtain” certainly deserves the appreciation, familiarity and application prospects for medical and research investigators worldwide.
Export Options
About this article
Cite this article as:
Silin S. Dmytro, Lyubomska V. Oksana, Ershov I. Feliks, Frolov M. Valeriy and Kutsyna A. Galyna, Synthetic and Natural Immunomodulators Acting as Interferon Inducers, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846847
DOI https://dx.doi.org/10.2174/138161209787846847 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Medium-term Culture of Normal Human Oral Mucosa: A Novel Three-dimensional Model to Study the Effectiveness of Drugs Administration
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry An Unexpected Diagnosis of Liver Metastases on a Bone Scan
Current Radiopharmaceuticals From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development
Current Women`s Health Reviews HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry